Related Experiment Video
Updated: May 2, 2026
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
[Interleukin-7, a new immunoadjuvant for the treatment of septic shock]
Guillaume Monneret1, Astrid Villars-Méchin2, Julie Demaret1
1Hospices civils de Lyon, hôpital Edouard Herriot, laboratoire d'immunologie cellulaire, 5, place d'Arsonval, 69437 Lyon Cedex 03, France - EAM 4174 Hémostase, sepsis, inflammation, Hospices civils de Lyon, université Lyon I, Lyon, France.
Sepsis-induced immunosuppression is a new paradigm in sepsis pathophysiology. This up-to-date review integrates recent facts in the field. It focuses on immune dysfunctions described so far in septic patients (especially regarding T lymphocytes), on the mechanisms sustaining this immune failure, on the monitoring of the pro-/anti-inflammatory balance rapidly changing over time and on new promising therapeutic avenues emerging from those recent findings. Of them, the case of interleukin-7 is more specifically envisaged.
Sepsis-induced immunosuppression is a new paradigm in sepsis pathophysiology. This up-to-date review integrates recent facts in the field. It focuses on immune dysfunctions described so far in septic patients (especially regarding T lymphocytes), on the mechanisms sustaining this immune failure, on the monitoring of the pro-/anti-inflammatory balance rapidly changing over time and on new promising therapeutic avenues emerging from those recent findings. Of them, the case of interleukin-7 is more specifically envisaged.
